Retraction Note to: Volume therapy in the intensive care patient – we are still confused, but. (Intensive Care Medicine, (2000), 26, 9, (1181-1192), 10.1007/s001340000625);Volume therapy in the intensive care patient - We are still confused, but ...

Intensive Care Medicine

Volumn 26, Issue 9, 2000, Pages 1181-1192

  Boldt, Joachim ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

Albumin; Colloids; Crystalloids; Gelatin; Intensive care medicine; Volume replacement

Indexed keywords

ALBUMIN; GELATIN;

BLOOD TRANSFUSION; COLLOID; CRYSTALLOID; FLUID THERAPY; HEMOSTASIS; HYPOVOLEMIA; INTENSIVE CARE; REVIEW; SUBSTITUTION THERAPY;

EID: 0033806367     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-020-06068-5     Document Type: Erratum

References (137)

1. Strategies of volume therapy in sepsis and systemic inflammatory response syndrome
2. Fluid resuscitation of shock: Current controversies
3. Fluid restoration in septic shock: No solution yet
4. The colloid-crystalloid controversy
5. Fluid resuscitation with colloids or crystalloids in critically ill patients: A systematic review of randomised trials
6. Human albumin administration in critically ill patients: Systematic review of randomised controlled trials
7. Crystalloids versus colloids in fluid resuscitation: A systematic review
8. Crystalloid versus colloid fluid resuscitation: A meta-analysis of mortality
9. Fluid resuscitation in circulatory shock: A comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolaemic and septic shock
10. Crystalloid versus colloid fluid resuscitation of patients with severe pulmonary insufficiency
11. A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapy
12. Crystalloid-colloid controversy revisited
13. Immune consequences of hypovolaemic shock and resuscitation
14. Mechanism of immunologic suppression in burn injury
15. Neurohormonal regulation after trauma. Circulating cytokines may also contribute to an activated sympathetic-adrenal control
16. Endocrine changes with critical illness
17. Interaction between the adrenergic and the renin-angiotensin systems
18. Endothelin: Systemic arterial and pulmonary effects of a new peptide with biologic properties
19. The control of production and release of haemostatic factors in the endothelial cell
20. Endothelium-dependent vascular responses
21. Regulatory functions of the vascular endothelium
22. On the absorption of fluids from the connective tissue spaces
23. Pulmonary edema during volume infusion
24. Colloid osmotic pressure as a prognostic indicator of pulmonary edema and mortality in the critically ill
25. Albumin and colloid osmotic pressure. Implications for fluid resuscitation
26. Quantitative evidence of microcirculatory compromise in skeletal muscle of normotensive, hyperdynamic sepsis
27. Issues in colloid and transfusion therapy of sepsis
28. Fluid therapy in septic shock
29. Increased vascular permeability: A major cause of hypalbuminaemia in disease and injury
30. Cardiovascular determinants of the haemodynamic response to acute endotoximia in the dog
31. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis
32. The role of the microcirculation in the multi-organ dysfunction syndrome
33. Capillary leak, oedema and organ failure: Breaking the triad
34. Practice parameters for hemodynamic support of sepsis in adult patients in sepsis
35. Cardiovascular and coronary physiology of acute isovolemic hemodilution: A review of non-oxygen-carrying and oxygen-carrying solutions
36. Critical haemoglobin concentration in anaesthetized dogs: Comparison of two plasma substitutes
37. A multicenter randomized, controlled clinical trial of transfusion requirements in critical care
38. Effects of red cell transfusion on oxygen consumption following fluid resuscitation in septic shock
39. Blood transfusion and oxygen consumption in surgical sepsis
40. Effect of stored-blood transfusion in oxygen delivery in patients with sepsis
41. Infection or suspected infection after hip replacement with autologous or homologous blood transfusions
42. Blood transfusion-induced immunomodulation
43. Transfusion medicine. I. Blood transfusion
44. Transfusion medicine. II. Blood conservation
45. Colloids versus crystalloids
46. Volume substitution in shock
47. Microcirculatory perfusion during volume therapy
48. Haemorrhage produces depression in microvascular blood flow which persist despite fluid resuscitation
49. The crystalloid versus colloid controversy: Present status
50. Clinical pharmacokinetics and pharmacodynamics of colloidal plasma volume expanders
51. Survey of colloid usage in British intensive care units
52. Volume replacement strategies on intensive care units: Results from a postal survey
53. Albumin supplementation in the critically ill. A prospective, randomized trial
54. Efficacy of albumin supplementation in the surgical intensive care unit: A prospective, randomized study
55. Randomized, double-blind study of intervenous human albumin in hypoalbuminemic patients receiving total parenteral nutrition
56. Dextran versus HES in inhibition of post-ischaemic leucocyte adherence in striated muscle
57. Pharmacological characteristics of artificial colloids
58. Plasma expanders and bleeding
59. Severe dextran-induced anaphylayctic/anaphylactoid reaction in spite of hapten prophylaxis
60. Effect of 6% hydroxyethyl starch and 3% modified fluid gelatin on intravascular volume and coagulation during intraoperative haemodilaution
61. The new generation gelatins
62. Reactions to gelatin plasma expanders
63. HES 200/0.5 is not HES 200/0.5 - Influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on haemorheology, coagulation and elimination kinetics
64. An international view of hydroxyethyl starches
65. In vivo investigation into the effects of haemodilution with hydroxyetyhl starch (200/0.5) and normal saline on coagulation
66. Haemodilution induces a hypercoagulable state
67. Effects of progressive haemodilution with hydroxyethyl starch, gelatin and albumin on blood coagulation
68. Differential effects of serial haemodilution with hydroxyethyl starch, albumin, and 0.9% saline on whole blood coagulation
69. Effect of dextran on factor VII (antihaemophilic factor) and platelet function
70. A study of haemostasis following use of high doses of hydroxyethyl starch 120 and dextran in major laparotomies
71. Thrombelastogram reveals hypercoagulability after administration of gelatin solution
72. Effects of gelatin-based resuscitation fluids on platelet aggregation
73. Reduced quality of clot formation with gelatin-based plasma substitutes
74. Impaired haemostasis by intravenous administration of a gelatin-based plasma expander in human subjects
75. Hydroxyethylstarch: Safe or not?
76. Intraoperative hetastarch infusion impairs haemostasis after cardiac surgery operations
77. Development of a von Willebrand-like syndrome after prolonged use of hydroxyethyl starch
78. Platelet function defects: A clinical review
79. Influence of different intravascular volume therapy on platelet function in patients undergoing cardiopulmonary bypass
80. The effect of hydroxyethyl starch on platelet aggregation in vitro
81. All medium starches are not the same: Influence of hydroxyethyl substitution of hydroxyethyl starch on plasma volume, haemorrheologic conditions, and coagulation
82. Coagulation disorders caused by hydroxyethyl starch
83. Effects of hetastarch and albumin on coagulation in patients with septic shock
84. Crystalloid versus colloid: All colloids are not created equal
85. The advantages of a narrow range medium molecular weight hydroxyethyl starch for volume maintenance in a porcine model of fecal peritonitis
86. Plugging the leaks? New insights into synthetic colloids
87. Pentafraction reduces the lung lymph response after endotoxin administration in the ovine model
88. Limiting edema in neonatal cardiopulmonary bypass with narrow range molecular weight hydroxyethyl starch
89. Colloidosmotic pressure and extravascular lung water after extracorporeal circulation
90. Hydroxyethyl starch macromolecules reduce myocardial reperfusion injury
91. Acute renal failure after infusion of gelatins
92. Pathophysiology and prevention of dextran-40-induced anuria
93. Acute renal failure precipitated by elevated colloid osmotic pressure
94. Dextran-40, acute renal failure, and elevated plasma oncotic pressure
95. Elevated urinary specific gravity in acute oliguric renal failure due to hetastarch administration
96. Hydroxyethyl starch and osmotic-nephrosis-like lesions in kidney transplantation
97. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients
98. Volume therapy in the critically ill: Is there a difference?
99. Current prospects for the treatment of clinical sepsis
100. An experimental study of susceptibility to infection after haemorrhagic shock
101. Effects of trauma, duration of hypotension, and resuscitation regimen on cellular immunity after hemorrhagic shock
102. Fluid resuscitation attenuates early cytokine mRNA expression after peritonitis
103. The effect of hydroxyethyl starch and other plasma volume substitutes on endothelial cell activation; An in vitro study
104. Effects of resuscitation fluids on T cell immune response
105. Monocyte chemotaxis and chemotactic cytokine release after exposure of hydroxyethyl starch
106. Hydroxethylstarch administration does not depress reticuloendothelial function or increase mortality from sepsis
107. Praoperative Eigenblutspende, der Einfluss von Hydroxethylstarke auf Retikuloendothelialsystem und Opsonine
108. Incidence and severity of anaphylactoid reactions to colloid volume substitution
109. Toxic effects of colloids in the intensive care unit
110. Reactions anaphylactoides aux subitutes colloidaux du plasma: Incidence, facteurs de risque, mecanismes
111. Severe anaphylactoid reaction to hydroxyethyl starch
112. Pigs are not humans
113. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
114. Crystalloid or colloid resuscitation. Are we any wiser?
115. Systemic haemodynamic abnormalities and vasopressor therapy in sepsis and septic shock
116. The role of gut mucosal hypoperfusion in the pathogenesis of postoperative organ dysfunction
117. Comparison of gastric intramucosal pH with measures of oxygen transport and consumption in critically ill patients
118. Splanchnic perfusion in shock
119. Comparison of commonly used clinical indicators of hypovolaemia with gastrointestinal tonometry
120. Gastric intramucosal pH changes after volume replacement with hydroxyethyl starch or crystalloid in patients undergoing elective abdominal aortic aneurysm repair
121. Predicting outcome after cardiac surgery: Comparison of global haemodynamic and tonometric variables
122. Effects of pentastarch and albumin infusion on cardiorespiratory function and coagulation in patients with severe sepsis and systemic hypoperfusion
123. Comparison of hydroxyethylstarch and lactated Ringer's solution on haemodynamics and oxygen transport of critically ill patients in prospective crossover studies
124. Colloid solutions in the critically ill. A randomised comparison of albumin and polygeline. 1. Outcome and duration of stay in the intensive care unit
125. Colloid solutions in the critically ill. A randomised comparison of albumin and polygeline. 2. Serum albumin concentration and incidences of pulmonary edema and acute renal failure
126. Comparison of the haemodynamic and oxygen transport responses to modified fluid gelatin and hetastarch in critically ill patients: A prospective, randomized trial
127. Influence of different volume therapies and pentoxifylline infusion on circulating soluble adhesion molecules in critically ill patients
128. The effects of albumin versus hydroxyethyl starch solution on cardiorespiratory and circulatory variables in critically ill patients
129. Influence of different volume therapy regimens on regulators of circulation in the critically ill
130. Influence of different volume therapies on platelet function in the critically ill
131. Influence of volume therapy and pentoxifylline infusion on circulating adhesion molecules in trauma patients
132. Distribution of normal saline and 5% albumin infusions in septic patients
133. A paradigm for consensus - The university hospital consortium guidelines for the use of albumin, nonprotein colloids, and crystalloid solutions
134. Fluid management in ARDS: 'Keep them dry' or does it matter?
135. Improved outcome based on fluid management in critically ill patients requiring pulmonary artery catheterization
136. Albumin and nonprotein colloid solution use in US academic health centers
137. Albumin abuse in intensive care medicine